Treatment of Subacute Cutaneous Lupus Erythematosus with Severe or Widespread Skin Lesions, Risk of Scarring, or Risk of Systemic Progression

This protocol is for patients with subacute cutaneous lupus erythematosus (SCLE) whose disease is severe or widespread, or who carry a meaningful risk of scarring or of progressing to systemic involvement. This clinical picture warrants a structured systemic treatment approach.

Clinical Scenario

Patients present with severe or widespread cutaneous lupus erythematosus skin lesions, and may additionally be at risk of scarring or at risk of developing systemic disease. These features define a population in whom long-term systemic therapy and sustained disease control are central treatment goals.

Treatment Approach (partial overview)

Antimalarial agents serve as the cornerstone of long-term systemic treatment in this group. For active, severe, or widespread lesions, additional systemic agents are introduced alongside antimalarials — the full protocol details the specific agents used, their sequencing, and the clinical criteria that guide each decision.

The complete regimen, including agent selection, route, and decision algorithm, is available via the protocol below.

Instant Access to Structured Evidence-Based Regimens

References

We recommend antimalarials as first-line and long-term systemic treatment in all CLE patients with severe or widespread skin lesions, in particular in patients with the risk of scarring and development of systemic disease.
In severe or widespread active CLE lesions, systemic corticosteroids are recommended as first-line treatment in addition to antimalarials.
We recommend MTX up to 20 mg per week as a second-line treatment, primarily in SCLE patients, preferably subcutaneously and in addition to antimalarials.

View source ↗